Data from Pharmawand - Curated by Marshall Pearce - Date added 13 August 2017

Stimwave LLC, a leading innovator in wireless medical device technology and independent research institute, has received FDA 510(k) clearance for the first wireless, micro-technology neuromodulation device that can enable ongoing full-body MRI scans under certain scanning conditions for the relief of chronic peripheral nerve pain.

Representing a life-changing technological breakthrough for the more than 400 million people worldwide who suffer from severe intractable chronic pain, the StimQ Peripheral Nerve Stimulator (PNS) System offers an alternative for those who do not want to rely on invasive surgical procedures or ongoing opioid treatments. The smallest neuromodulation device available, the StimQ device can be placed in a minimally-invasive, outpatient procedure for the treatment of various pain syndromes, including, but not limited to: shoulder pain, upper extremity neuropathy, mid and lower back pain, and lower extremity neuropathy. The new FDA clearance enables the pain sufferer to have frequent and necessary MRI scans of any part of their body without removing the implant.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Pain, Agitation and Delirium (PAD) Management

Pain, Agitation and Delirium (PAD) Management

Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.

+ 4 more

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Breakthrough Cancer Pain Learning Zone

Breakthrough Cancer Pain Learning Zone

Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.

Load more

Related Content